Using Pyruvate Kinase as a Predictor for Patient With Endometrial Cancer Having Complex Hyperplasia With Atypia to Prevent Hysterectomy and Preserve Fertility: Retrospective Immunohistochemical Study

Objectives: To explore whether the metabolic switches proceed or succeed the histological changes in precancerous lesions. To validate pyruvate kinase isoform 1 (PKM1) and pyruvate kinase isoform 2 (PKM2) as a histological biomarker to predict the progression of endometrial hyperplasia into invasive cancer status. Methods: The records of 56 patients with a primary diagnosis of complex hyperplasia with atypia after endometrial biopsy were selected and analyzed retrospectively. A set of 3 consecutive sections at 4-μm thickness were cut and studied with immunohistochemical stains. From each case, 2 to 3 fields with a diagnosis of complex hyperplasia with atypia were selected and compared. A single pathologist blinded to the final diagnosis assigned the scoring. Results: Positive immunostaining for PKM1 was observed in 31.25% (10 out of 32) of initial endometrial biopsy with the diagnosis of complex hyperplasia with atypia and final diagnosis of endometrial cancer, while 91.67% (out of 24) of patients with final diagnosis of negative endometrial cancer had endometrial biopsy with positive PKM1 staining (P < .001). Positive immunostaining for PKM2 was observed in 100% of patient with endometrial biopsy result of endometrial hyperplasia with atypia (56 of 56). Conclusions: Lack of staining with PKM1 expression may help to predict the fate of endometrial hyperplasia. The disappearance of this marker is associated with the progression of hyperplasia toward cancer phenotype. Further studies are needed to understand the causes and potential mechanisms for suppressing Pyruvate Kinase Isoform 1 expression in endometrial hyperplasia.

[1]  S. Mazurek.  Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. , 2011, The international journal of biochemistry & cell biology.

[2]  H. Lehrach,et al.  No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis , 2011, Oncotarget.

[3]  T. Mak,et al.  Regulation of cancer cell metabolism , 2011, Nature Reviews Cancer.

[4]  A. Krainer,et al.  The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism , 2010, Proceedings of the National Academy of Sciences.

[5]  Jing Chen,et al.  Tyrosine Phosphorylation Inhibits PKM2 to Promote the Warburg Effect and Tumor Growth , 2009, Science Signaling.

[6]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[7]  T. Noguchi,et al.  Regulation of M2‐type pyruvate kinase mediated by the high‐affinity IgE receptors is required for mast cell degranulation , 2008, British journal of pharmacology.

[8]  D. Guo,et al.  Isoform‐specific interaction of pyruvate kinase with hepatitis C virus NS5B , 2008, FEBS letters.

[9]  H. Christofk,et al.  Pyruvate kinase M2 is a phosphotyrosine-binding protein , 2008, Nature.

[10]  Ru Wei,et al.  The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth , 2008, Nature.

[11]  S. Ishii,et al.  Modulation of M2‐type pyruvate kinase activity by the cytoplasmic PML tumor suppressor protein , 2008, Genes to cells : devoted to molecular & cellular mechanisms.

[12]  J. Troppmair,et al.  Regulation of pyruvate kinase type M2 by A-Raf: a possible glycolytic stop or go mechanism. , 2007, Anticancer research.

[13]  A. Hoshino,et al.  Regulation of Cell Proliferation by Interleukin-3-induced Nuclear Translocation of Pyruvate Kinase* , 2007, Journal of Biological Chemistry.

[14]  Chi V Dang,et al.  Cancer's molecular sweet tooth and the Warburg effect. , 2006, Cancer research.

[15]  M. Toepler,et al.  Pyruvatkinase M2 (Tumor M2-PK) im Stuhl als Screeningparameter für kolorektale Neoplasien. Eine Übersicht über bisher publizierte Daten , 2005 .

[16]  C. Boschek,et al.  Pyruvate kinase type M2 and its role in tumor growth and spreading. , 2005, Seminars in cancer biology.

[17]  M. Hoopmann,et al.  Tumor M2 pyruvate kinase--determination in breast cancer patients receiving trastuzumab therapy. , 2002, Cancer letters.

[18]  K. Usadel,et al.  The pyruvate kinase isoenzyme tumor M2 (Tu M2-PK) as a tumor marker for renal carcinoma. , 1999, Anticancer Research.

[19]  L. Banks,et al.  Modulation of type M2 pyruvate kinase activity by the human papillomavirus type 16 E7 oncoprotein. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[20]  S. Zeuzem,et al.  Value of the serum levels of the tumor marker TUM2-PK in pancreatic cancer. , 1997, Anticancer research.

[21]  Y. Shimada,et al.  Profiles of carbohydrate-metabolizing enzymes in human hepatocellular carcinomas and preneoplastic livers. , 1988, Cancer research.

[22]  T. Tanaka,et al.  The L- and R-type isozymes of rat pyruvate kinase are produced from a single gene by use of different promoters. , 1987, The Journal of biological chemistry.

[23]  R. Orlando,et al.  Expression of multimolecular forms of pyruvate kinase in normal, benign, and malignant human breast tissue. , 1982, Cancer research.

[24]  O. Warburg.  [Origin of cancer cells]. , 1956, Oncologia.

[25]  O. Warburg,et al.  THE METABOLISM OF TUMORS IN THE BODY , 1927, The Journal of general physiology.

[26]  Jungho Kim,et al.  Pyruvate kinase isozyme type M2 (PKM2) interacts and cooperates with Oct-4 in regulating transcription. , 2008, The international journal of biochemistry & cell biology.

[27]  D. Mochly‐Rosen,et al.  Use of a novel method to find substrates of protein kinase C delta identifies M2 pyruvate kinase. , 2007, The international journal of biochemistry & cell biology.

[28]  H. Grimm,et al.  Tumor M2-pyruvate kinase in lung cancer patients: immunohistochemical detection and disease monitoring. , 2002, Anticancer research.

[29]  E. Eigenbrodt,et al.  Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells. , 1992, Critical reviews in oncogenesis.